Alto Neuroscience (NYSE:ANRO) Stock Price Up 8.4% - What's Next?

Alto Neuroscience logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Alto Neuroscience shares rose 8.4% in mid-day trading, reaching $26.998, while trading volume was about 89% below its average.
  • Analysts’ consensus remains Moderate Buy, with an average price target of $37.88; ratings include eight Buys, two Holds, and one Sell.
  • The company reported a quarterly loss of $0.54 per share, beating consensus estimates for a $0.67 loss. CFO Nicholas Smith also sold 24,056 shares, reducing his position by 50%.
  • Five stocks we like better than Alto Neuroscience.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) traded up 8.4% during mid-day trading on Wednesday. The company traded as high as $26.05 and last traded at $26.9980. Approximately 48,275 shares were traded during trading, a decline of 89% from the average daily volume of 438,364 shares. The stock had previously closed at $24.91.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Wall Street Zen cut Alto Neuroscience from a "hold" rating to a "sell" rating in a report on Saturday, September 12th. HC Wainwright restated a "buy" rating on shares of Alto Neuroscience in a report on Thursday, November 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. BTIG Research reiterated a "buy" rating and set a $37.00 price target on shares of Alto Neuroscience in a research note on Wednesday, November 11th. Finally, Wedbush raised their price target on Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a research note on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $37.88.

Read Our Latest Analysis on Alto Neuroscience

Alto Neuroscience Price Performance

The company has a debt-to-equity ratio of 0.04, a current ratio of 18.12 and a quick ratio of 18.12. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -11.00 and a beta of 1.42. The company's 50-day simple moving average is $25.99 and its 200-day simple moving average is $24.74.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.13. On average, equities research analysts anticipate that Alto Neuroscience, Inc. will post -2.48 EPS for the current year.

Insider Buying and Selling at Alto Neuroscience

In other news, CFO Nicholas Smith sold 24,056 shares of the firm's stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the transaction, the chief financial officer directly owned 24,060 shares in the company, valued at approximately $621,229.20. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 11.25% of the company's stock.

Institutional Trading of Alto Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new position in shares of Alto Neuroscience in the 2nd quarter valued at $2,014,000. AWM Investment Company Inc. acquired a new stake in shares of Alto Neuroscience during the second quarter worth about $2,111,000. Jennison Associates LLC bought a new position in shares of Alto Neuroscience during the 1st quarter valued at about $8,687,000. Perceptive Advisors LLC lifted its holdings in shares of Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company's stock valued at $45,182,000 after purchasing an additional 225,500 shares in the last quarter. Finally, Orbimed Advisors LLC grew its position in shares of Alto Neuroscience by 34.0% in the 1st quarter. Orbimed Advisors LLC now owns 167,500 shares of the company's stock valued at $3,765,000 after purchasing an additional 42,500 shares during the period.

Alto Neuroscience Company Profile

(Get Free Report)

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto's approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alto Neuroscience Right Now?

Before you consider Alto Neuroscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.

While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines